NCT01408329

Brief Summary

Cyclic Variation in Altitude Conditioning (CVAC) is a new technique that uses a pod-like device to expose users to controlled fluctuations in air pressure. It is designed to promote quicker altitude acclimatization, thus promoting improvements in exercise capacity at altitude and, possibly, at sea level. However, over the past few years, anecdotal stories from users of the device suggest that the CVAC treatments might be causing changes beyond the expected endurance exercise performance benefits. Therefore, the purpose of the study is to obtain data on some of the previous anecdotal claims regarding the device (e.g. increases in strength, improved glucose tolerance, reduction of neuropathic pain and decreased joint swelling) as well as to obtain broad questionnaire data in order to identify more specific variables to investigate in future studies.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2007

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2009

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

July 28, 2011

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 3, 2011

Completed
4.1 years until next milestone

Results Posted

Study results publicly available

September 22, 2015

Completed
Last Updated

September 22, 2015

Status Verified

August 1, 2015

Enrollment Period

2.6 years

First QC Date

July 28, 2011

Results QC Date

May 17, 2013

Last Update Submit

August 19, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Plasma Glucose Concentration

    Glucose measurements were made at baseline, 3, 6, & 10 weeks. Blood was collected consistently after a 10-12 h fast the morning after a CVAC session (except for baseline).

Study Arms (2)

Control

SHAM COMPARATOR

Sham altitude changes - The CVAC device consists of a small pod-like chamber attached to a computer system that controls a strong pump that can draw air rapidly out of the chamber to increase the simulated altitude. The sham-treated group (SH) was exposed to regular, slowly-fluctuating pressures that reached a maximum altitude of 607 m for all 30 sessions. Sham sessions mimicked the noises and initial pressure-change sensations created in the active sessions, thus giving naıve subjects the impression that they were experiencing altitude treatment. All subjects were blind to their elevation throughout the intervention.

Device: CVAC Device (Cyclic Variations in Altitude Conditioning)

Hypoxic intervention

EXPERIMENTAL

Cyclic Hypobaric Hypoxia (CHH) subjects were given 40 min sessions inside the CVAC device per day (two 20 min sessions sequentially per day), 3 days a week for 10 weeks, for a total of 30 sessions or 20 hours. After familiarization sessions, pre-programmed sessions were administered, progressing from Tier 1 to 5. Subjects rotated through three pre-programmed sessions per Tier and each session varied the pattern and rate of hypoxic fluctuations, so that subjects would experience a constantly changing stimulus at each elevation. Five weeks were allotted to progress from Tier 1 (3048 m) to Tier 4 (5486 m). At Tier 5 (6096 m), there was an additional 5 weeks of exposure.

Device: CVAC Device (Cyclic Variations in Altitude Conditioning)

Interventions

A hypobaric hypoxia chamber

ControlHypoxic intervention

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy middle aged men at risk for metabolic syndrome

You may not qualify if:

  • Uncontrolled hypertension,
  • sensitive ears,
  • anything that would preclude person from sustaining rapid pressure changes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypoxia

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Limitations and Caveats

Small Sample size

Results Point of Contact

Title
Anne L Friedlander
Organization
Stanford University

Study Officials

  • Anne Friedlander, PhD

    Veterans Affairs Palo Alto Health Care System

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consulting Professor

Study Record Dates

First Submitted

July 28, 2011

First Posted

August 3, 2011

Study Start

January 1, 2007

Primary Completion

August 1, 2009

Study Completion

August 1, 2010

Last Updated

September 22, 2015

Results First Posted

September 22, 2015

Record last verified: 2015-08